OLMA Olema Oncology, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1750284 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-57.3%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-69.8%
ROA-59.5%
ROIC (approx.)-67.3%
Asset turnover—
Leverage & solvency
Liabilities / assets16.4%
Debt / equity0.00x
Current ratio6.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-14.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $157.70M | $124.52M | $86.14M | $82.27M | $51.10M |
| SG&A expense | $21.00M | $17.74M | $18.82M | $24.71M | $20.39M |
| Operating income | -$178.70M | -$142.26M | -$104.96M | -$106.99M | -$71.49M |
| Pretax income | -$162.45M | -$129.47M | — | — | — |
| Income tax | $3,000 | $2,000 | $2,000 | $1,000 | — |
| Net income | -$162.45M | -$129.47M | -$96.66M | -$104.79M | -$71.10M |
| EBITDA | -$178.21M | -$141.87M | -$104.58M | -$106.63M | -$71.33M |
| EPS (basic) | -1.87 | -2.20 | -2.14 | -2.62 | -1.80 |
| EPS (diluted) | -1.87 | -2.20 | -2.14 | -2.62 | -1.80 |
| Weighted avg. shares (diluted) | 87.01M | 58.74M | 45.25M | 40.00M | 39.52M |
| Balance sheet | |||||
| Cash & equivalents | $48.30M | $139.48M | $68.54M | $23.70M | $13.81M |
| Short-term investments | $457.14M | $294.61M | $193.27M | $180.72M | $273.44M |
| Current assets | $515.45M | $438.47M | $266.51M | $208.90M | $290.69M |
| PP&E, net | $274,000 | $746,000 | $968,000 | $1.48M | $1.47M |
| Total assets | $533.43M | $450.98M | $276.94M | $215.65M | $295.94M |
| Current liabilities | $51.80M | $41.76M | $21.62M | $16.55M | $9.02M |
| Total liabilities | $54.87M | $42.02M | $23.05M | $18.10M | $11.38M |
| Shareholders' equity | $478.56M | $408.96M | $253.90M | $197.55M | $284.57M |
| Shares outstanding | 81.38M | 74.31M | 54.99M | 40.29M | 39.80M |
| Cash flow statement | |||||
| Operating cash flow | -$146.72M | -$104.35M | -$83.73M | -$82.06M | -$50.69M |
| Capital expenditure | — | $159,000 | — | $363,000 | $1.57M |
| Free cash flow | — | -$104.51M | — | -$82.43M | -$52.27M |
| Investing cash flow | -$155.76M | -$93.53M | -$4.85M | $91.48M | -$275.44M |
| Financing cash flow | $211.30M | $268.82M | $133.41M | $476,000 | $1.39M |
| Depreciation & amortization | $490,000 | $393,000 | $377,000 | $357,000 | $163,000 |
| Stock-based compensation | $17.59M | $22.58M | $17.26M | $18.83M | $15.91M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.